Track topics on Twitter Track topics that are important to you
Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurovance also holds a substantial portfolio of research stage reuptake inhibitors.
A Series A1 funding round has pulled in an additional $5.5 million for Neurovance. -More-
Neurovance is a neuroscience-focused, clinical-stage biopharmaceutical company that specializes in triple reuptake inhibitors specifically optimized for adult attention deficit hy...
Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurov...
We have published hundreds of Neurovance, Inc. news stories on BioPortfolio along with dozens of Neurovance, Inc. Clinical Trials and PubMed Articles about Neurovance, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Neurovance, Inc. Companies in our database. You can also find out about relevant Neurovance, Inc. Drugs and Medications on this site too.
Latest News Clinical Trials Research Drugs Reports Corporate
Bioscience - any of the sciences that deal with living organisms. The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...